Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma
University of Washington
University of Washington
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Washington
City of Hope Medical Center
Hebei Medical University Fourth Hospital
Children's Oncology Group
Dana-Farber Cancer Institute
Emory University
Mayo Clinic
Fred Hutchinson Cancer Center
City of Hope Medical Center
Affiliated Hospital of Nantong University
City of Hope Medical Center
The Affiliated People's Hospital of Ningbo University
Fudan University
Fred Hutchinson Cancer Center
University of Washington
National Cancer Institute (NCI)
Jiangsu HengRui Medicine Co., Ltd.
Fred Hutchinson Cancer Center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Institute of Hematology & Blood Diseases Hospital, China
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Shandong University
The Affiliated People's Hospital of Ningbo University
The Affiliated People's Hospital of Ningbo University
Shandong University
University of Washington
The Affiliated People's Hospital of Ningbo University
Chongqing University Cancer Hospital
Chongqing University Cancer Hospital
Chongqing University Cancer Hospital
Fred Hutchinson Cancer Center
The First Hospital of Jilin University
Mabwell (Shanghai) Bioscience Co., Ltd.
The First Hospital of Jilin University
Xiamen Amoytop Biotech Co., Ltd.
Sun Yat-sen University
Fudan University
Peking University
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Emory University
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Tianjin Medical University Cancer Institute and Hospital
Ruijin Hospital
Prolong Pharmaceuticals
Peking University
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.